MEDDESKTOP: Health Canada Advisory, GlaxoSmithKline's Pr BENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behaviour, or Self-Injury.

Friday, April 05, 2019

Health Canada Advisory, GlaxoSmithKline's Pr BENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behaviour, or Self-Injury.

GlaxoSmithKline's Pr BENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behaviour, or Self-Injury -Health Canada

Health Canada Advisory

No comments:

Subscribe to: Post Comments (Atom)